Key Achievements
Xeedia has shown remarkable success over a short period from launching our first locally manufactured cardiovascular products to our new scientific office in Dubai.
2020 - 21
- Xeedia Pharmaceutical Company launch.
- Locally manufactured cardiovascular products launch.
2021 - 22
- Gastrointestinal Tract and Ortho product lines launch.
- Introduced Icosapent Ethyl (Exeedolip) to the Egyptian market for Hypertriglyceridemia.
- Top 100 pharmaceutical companies club member.
2022 - 23
- Established an independent business unit for the GIT - Orthopedic products.
- Introduced the fixed-dose combination of 40mg Rosuvastatin/10mg Ezetimibe to the Middle East.
- IQVIA: Xeedia is the 2nd most growing pharmaceutical company.
- (SOURCE: IMS -
IQVIA)
2024 - 25
- Set a cornerstone in Xeedia’s manufacturing facility in Egypt.
- Launched OMEGAL General Health product line.
- Started the diabetes market penetration through a late 2024 product launch.
2025 - 26
- New product launches in the Orthopedic, General Health, CVM, and Diabetes lines.
